The successful control of coronavirus disease 2019 (COVID-19) pandemic is not only
relying on the development of vaccines, but also depending on the storage,
transportation, and administration of vaccines. Ideally, nucleic acid vaccine should be
directly delivered to proper immune cells or tissue (such as lymph nodes). However,
current developed vaccines are normally treated through intramuscular injection, where
immune cells do not normally reside. Meanwhile, current nucleic acid vaccines must be
stored in a frozen state that may hinder their application in developing countries.
Here, we report a separable microneedle (SMN) patch to deliver polymer encapsulated
spike (or nucleocapsid) protein encoding DNA vaccines and immune adjuvant for efficient
immunization. Compared with intramuscular injection, SMN patch can deliver nanovaccines
into intradermal for inducing potent and durable adaptive immunity.
IFN-γ
+
CD4/8
+
and IL-2
+
CD4/8
+
T cells
or virus specific IgG are significantly increased after vaccination. Moreover,
in vivo
results show the SMN patches can be stored at room
temperature for at least 30 days without decreases in immune responses. These features
of nanovaccines-laden SMN patch are important for developing advanced COVID-19 vaccines
with global accessibility.